Fund managers back market darling Telix Pharmaceuticals

  • 📰 FinancialReview
  • ⏱ Reading Time:
  • 21 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 12%
  • Publisher: 90%

日本 ニュース ニュース

日本 最新ニュース,日本 見出し

A bevvy of healthcare analysts and Australian equities managers have profited from buying fast-rising oncology business Telix, after it unveiled strong sales.

Shares in Telix Pharmaceuticals have surged more than tenfold in five years as a record June quarter of sales supports phenomenal investor interest in the cancer diagnostic and treatment business.

Antares is among Australian equities managers such as Platinum Asset Management, Perennial Partners, Fidelity, Acorn Capital, and Wilson Asset Management that own Telix shares. “We still think shares have further upside,” said Mr Hamilton. “I think that first [June] quarter of commercial sales in Illucix show it’s a great product. It entered the market and got very good awareness of PSMA imaging.

 

コメントありがとうございます。コメントは審査後に公開されます。

tommyr345 still a puppet for asxlongtail Only biotech Tom covers strangely, share price is the same as last time you wrote a puff piece for him 🤡

このニュースをすぐに読めるように要約しました。ニュースに興味がある場合は、ここで全文を読むことができます。 続きを読む:

 /  🏆 2. in JP

日本 最新ニュース, 日本 見出し